Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.
Vallurupalli M, Berliner N. Vallurupalli M, et al. Blood. 2019 Nov 21;134(21):1783-1786. doi: 10.1182/blood.2019002289. Blood. 2019. PMID: 31537529 Free PMC article. Review.
Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-gamma (IFN-gamma), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis …
Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-gamma (IFN-gamma), which in November 2018 rece …
Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Wei A, Ma H, Li Z, Zhang L, Zhang Q, Wang D, Lian H, Zhang R, Wang T. Wei A, et al. Int J Hematol. 2020 Oct;112(4):568-576. doi: 10.1007/s12185-020-02936-4. Epub 2020 Jul 14. Int J Hematol. 2020. PMID: 32666469
To investigate the efficacy and safety of the Janus kinase inhibitor ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis (HLH) in children. We performed a retrospective analysis of ruxolitinib in children with recurrent …
To investigate the efficacy and safety of the Janus kinase inhibitor ruxolitinib in the treatment of recurrent or refractory hemop …
Successful salvage treatment with antithymocyte globulin for patients with early-onset hemophagocytic lymphohistiocytosis refractory to steroid and etoposide therapy following allogeneic hematopoietic stem cell transplantation.
Kakinoki Y, Ishio T, Kimura H, Shimono J, Miyashita N, Sekine T, Kasahara K. Kakinoki Y, et al. Bone Marrow Transplant. 2020 Jul;55(7):1479-1482. doi: 10.1038/s41409-020-0802-z. Epub 2020 Jan 28. Bone Marrow Transplant. 2020. PMID: 31992843 No abstract available.